- Category
- Small (2024-25)
- Udyam number
- UDYAM-KR-02-0028459

Posilive Pharmaceuticals LLP
About Posilive Pharmaceuticals LLP
Data last updated:
Posilive Pharmaceuticals LLP is a limited liability partnership (LLP) based in Bangalore, Karnataka, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 21 October 2014 and has been in existence for over 12 years.
The LLP is registered with the Registrar of Companies (ROC), Bangalore, under LLPIN AAC-8330. Its GSTIN is 29AAQFP4414K1ZQ (Karnataka).
The LLP has a total obligation of contribution of ₹57.5 Lakh. It is led by designated partners Raghavendra Jayakumar Yencharla and Hedna Vishnumurthy Santhrupth.
Its latest statement of accounts is for the year ended 31 March 2025. The registered office is at Bangalore, Karnataka.
As per the financials filed for FY 2022, the LLP reported a revenue of ₹11.66 Cr, a growth of 61% compared to the previous year. For the same year it recorded a net profit of ₹50.97 Lakh (net margin 4.4%) and EBITDA of -₹29.01 Lakh (EBITDA margin -2.5%). Revenue has grown at a compounded annual rate (CAGR) of 51% over three years and 46% over five years.
Court records list 2 cases involving the LLP, including 2 filed against it; 2 cases are pending.
Posilive Pharmaceuticals LLP is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-KR-02-0028459).
Recognitions & Rankings of Posilive Pharmaceuticals
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressNo.227 3rd Cross 6th Stage 3rd Block Chikkegowanapalya Thalaghatt, Apura, Bangalore, Karnataka, India – 560062
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Posilive Pharmaceuticals LLP FY 2025 filings available
Posilive Pharmaceuticals LLP reported revenue of ₹11.66 Cr (up 61% YoY) for FY 2022.
Compounded Annual Growth Rate (CAGR) of Posilive Pharmaceuticals LLP
Revenue has grown at a compounded annual rate (CAGR) of 46% over five years, including 61% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Posilive Pharmaceuticals LLP
| Statement of Account and Solvency | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Income and Expenditure | |||||
| Turnover | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Income | ₹11.66 Cr | •••• | •••• | •••• | •••• |
| Purchases and Direct Costs | •••• | •••• | •••• | •••• | •••• |
| Personnel Expenses | •••• | •••• | •••• | •••• | •••• |
| Administrative Expenses | •••• | •••• | •••• | •••• | •••• |
| Interest | •••• | •••• | •••• | •••• | •••• |
| Depreciation | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax | •••• | •••• | •••• | •••• | •••• |
| Profit After Tax | ₹50.97 Lakh | •••• | •••• | •••• | •••• |
| Profit Transferred to Partners | •••• | •••• | •••• | •••• | •••• |
| Assets and Liabilities | |||||
| Partners' Contribution | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Secured Loans | •••• | •••• | •••• | •••• | •••• |
| Unsecured Loans | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Other Liabilities and Provisions | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Loans and Advances | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Posilive Pharmaceuticals LLP
| Statement of Account and Solvency | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | FY 2017-18 |
|---|---|---|---|---|---|
| Profitability | |||||
| Net Profit Margin | 4.4% | •••• | •••• | •••• | •••• |
| Return on Partners' Funds | •••• | •••• | •••• | •••• | •••• |
| Return on Assets | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt to Partners' Funds | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Turnover Growth | •••• | •••• | •••• | •••• | •••• |
| Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form 8. The full year-wise statements and ratios of Posilive Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Designated Partners of Posilive Pharmaceuticals LLP
Posilive Pharmaceuticals has 2 current designated partners and 1 former designated partner. Current designated partners are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Raghavendra Jayakumar Yencharla | Designated Partner | 21 Oct 2014 | 12 Years 0 Months | Current |
| Hedna Vishnumurthy Santhrupth Also directs: Blossom Palms LLP, Prestine Envirno Private Limited, Arqive Properties Development Private Limited and 1 more | Designated Partner | 21 Oct 2014 | 12 Years 0 Months | Current |
Ownership and Shareholding of Posilive Pharmaceuticals LLP
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Posilive Pharmaceuticals LLP
Posilive Pharmaceuticals LLP does not have any charges (loans) registered with the Registrar of Companies.
Legal Cases of Posilive Pharmaceuticals LLP
Posilive Pharmaceuticals LLP has 2 court cases on record: 2 filed against it. All cases are pending. Status as checked on 21 Sep 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 2 | 2 | 2 |
Cases on record (2 of 2)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (CRR) | Filed against the company by Sun Pharma Laboratories Limited | Pending |
| Bombay High Court | Court case (LPETN) | Filed against the company by Sun Pharma Laboratories Limited | Pending |
Full case history
All 2 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Posilive Pharmaceuticals LLP
Employment history and EPFO contributions of people linked to Posilive Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Posilive Pharmaceuticals LLP
Posilive Pharmaceuticals LLP has 3 designated partner changes on record since 2014: 3 appointments. The latest: Hedna Vishnumurthy Santhrupth was appointed as Designated Partner on 21 Oct 2014.
Credit Ratings, Litigation & Regulatory Alerts for Posilive Pharmaceuticals LLP
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Posilive Pharmaceuticals LLP
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Posilive Pharmaceuticals LLP
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Posilive Pharmaceuticals LLP
Posilive Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAQFP4414K1ZQ | Karnataka | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Posilive Pharmaceuticals LLP
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Posilive Pharmaceuticals LLP
Posilive Pharmaceuticals is an active limited liability partnership based in Bangalore, Karnataka, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 21 October 2014 (12+ years old) and is registered under LLPIN AAC-8330.
Posilive Pharmaceuticals reported revenue of ₹11.66 Cr for FY 2022 (up 61% YoY).
Posilive Pharmaceuticals has 2 current designated partners:
- Raghavendra Jayakumar Yencharla - Designated Partner
- Hedna Vishnumurthy Santhrupth - Designated Partner
Posilive Pharmaceuticals reported a net profit of ₹50.97 Lakh (net margin 4.4%) and EBITDA of -₹29.01 Lakh (EBITDA margin -2.5%) for FY 2022, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Posilive Pharmaceuticals is 51% over three years and 46% over five years. In the latest year (FY 2022) revenue rose 61%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Posilive Pharmaceuticals is 29AAQFP4414K1ZQ, registered in Karnataka.
The LLPIN (Limited Liability Partnership Identification Number) of Posilive Pharmaceuticals is AAC-8330. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Posilive Pharmaceuticals has 2 court cases on record: 2 filed against it. 2 are pending.
Posilive Pharmaceuticals was incorporated on 21 October 2014, making it 12+ years old. It is registered with the Registrar of Companies, Bangalore.
Hedna Vishnumurthy Santhrupth was appointed as Designated Partner on 21 Oct 2014. Manojkumar Vaijanathrao Bhutte was appointed as Partner on 21 Oct 2014. Raghavendra Jayakumar Yencharla was appointed as Designated Partner on 21 Oct 2014.